These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3743371)

  • 1. Synthesis of reactive metabolite-analogues of cyclophosphamide for comparisons of NMR kinetic parameters and anticancer screening data.
    Ludeman SM; Boyd VL; Regan JB; Gallo KA; Zon G; Ishii K
    Drugs Exp Clin Res; 1986; 12(6-7):527-32. PubMed ID: 3743371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of "phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide.
    Ludeman SM; Boyd VL; Regan JB; Gallo KA; Zon G; Ishii K
    J Med Chem; 1986 May; 29(5):716-27. PubMed ID: 3701785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and antitumor properties of activated cyclophosphamide analogues.
    Borch RF; Canute GW
    J Med Chem; 1991 Oct; 34(10):3044-52. PubMed ID: 1920355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
    Friedman OM; Wodinsky I; Myles A
    Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solutions.
    Gilard V; Martino R; Malet-Martino M; Niemeyer U; Pohl J
    J Med Chem; 1999 Jul; 42(14):2542-60. PubMed ID: 10411475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
    Maki PA; Sladek NE
    Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
    Boal JH; Ludeman SM; Ho CK; Engel J; Niemeyer U
    Arzneimittelforschung; 1994 Jan; 44(1):84-93. PubMed ID: 8135883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro.
    Erickson LC; Ramonas LM; Zaharko DS; Kohn KW
    Cancer Res; 1980 Nov; 40(11):4216-20. PubMed ID: 7471062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
    Jain M; Fan J; Baturay NZ; Kwon CH
    J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
    Low JE; Borch RF; Sladek NE
    Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways.
    Zon G; Ludeman SM; Brandt JA; Boyd VL; Ozkan G; Egan W; Shao KL
    J Med Chem; 1984 Apr; 27(4):466-85. PubMed ID: 6708049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
    Lelieveld P; van Putten LM
    Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide.
    Zon G; Ludeman SM; Sweet EM; Egan W; Phillips LR
    J Pharm Sci; 1982 Apr; 71(4):443-6. PubMed ID: 7086655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.
    Hohorst HJ; Draeger U; Peter G; Voelcker G
    Cancer Treat Rep; 1976 Apr; 60(4):309-15. PubMed ID: 1277206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
    Kwon CH; Maddison K; LoCastro L; Borch RF
    Cancer Res; 1987 Mar; 47(6):1505-8. PubMed ID: 3815352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, activation, and cytotoxicity of aldophosphamide analogues.
    Borch RF; Valente RR
    J Med Chem; 1991 Oct; 34(10):3052-8. PubMed ID: 1920356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of stereochemistry on the oxidative metabolism of the cyclophosphamide metabolite aldophosphamide.
    Habib AD; Boal JH; Hilton J; Nguyen T; Chang YH; Ludeman SM
    Biochem Pharmacol; 1995 Jul; 50(3):429-33. PubMed ID: 7646546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and study of a spin-labeled cyclophosphamide analogue, 3-(1-oxy-2,2,6,6-tetramethyl-4-piperidinyl)cyclophosphamide.
    Tsui FP; Robey FA; Engle TW; Ludeman SM; Zon G
    J Med Chem; 1982 Sep; 25(9):1106-10. PubMed ID: 7131492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential cytotoxicity and DNA cross-linking produced by polymeric and monomeric activated analogues of cyclophosphamide in mouse L1210 leukemia cells.
    Ramonas LM; Erickson LC; Klesse W; Kohn KW; Zaharko DS
    Mol Pharmacol; 1981 Mar; 19(2):331-6. PubMed ID: 7231393
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
    Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
    Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.